RVPH241220P5000
- 0.00
- 0.000.00%
Reviva Pharmaceuticals Newsroom
8-K: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Reviva Pharm Holdings 3Q Loss/Shr 25c >RVPH
Reviva Pharm Holdings Price Target Maintained With a $15.00/Share by D. Boral Capital
Reviva Pharm Holdings Is Maintained at Buy by D. Boral Capital
Press Release: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Express News | Reviva Pharmaceuticals Q3 Net Income USD -8.4 Million
Express News | Reviva Pharmaceuticals Q3 EPS USD -0.25
Express News | Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
10-Q: Q3 2024 Earnings Report
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $15 Price Target
Maxim Group Maintains Reviva Pharmaceuticals(RVPH.US) With Hold Rating
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
Reviva to Participate in the UBS Global Healthcare Conference
12 Health Care Stocks Moving In Thursday's After-Market Session
Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
Reviva Pharm Holdings Initiated at Buy by EF Hutton
Express News | Reviva Pharmaceuticals Holdings, Inc. - Statistically Significant Vocal Biomarker Data Reinforce Efficacy of Brilaroxazine
Express News | Reviva Pharmaceuticals Holdings, Inc.: Additional Vocal Biomarker Data From Ongoing Open Label Extension Study Expected Q4 2024
Maxim Group Maintains Reviva Pharmaceuticals(RVPH.US) With Hold Rating
Maxim Group analyst Jason McCarthy maintains $Reviva Pharmaceuticals(RVPH.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 24.3% and a total average return of -22.